Mark Mayson, MD
Pulmonary Disease · Columbia, SCNPI 1962480889
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,245 of the $85,574 with a category attached, or 78.6%. AstraZeneca accounts for 84.8% of it on its own, with 35 other manufacturers making up the rest. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 714 payments — averaging $119.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$73K
- Sanofi$2K
- GSK$2K
- Insmed, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$863
- Actelion Pharmaceuticals US, Inc.$819
- plus $6K from 30 others
What the payments were for
- Consulting fees$2000%
- Speaking & faculty fees$67,24579%
- Travel & lodging$9101%
- Food & beverage$17,09520%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 188 | $72,580 |
| Sanofi | 40 | $2,255 |
| GSK | 96 | $1,590 |
| Insmed, Inc. | 47 | $1,046 |
| Regeneron Healthcare Solutions, Inc. | 26 | $863 |
| Actelion Pharmaceuticals US, Inc. | 29 | $819 |
| United Therapeutics Corporation | 26 | $759 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $713 |
| Merck | 28 | $567 |
| Electromed, Inc. | 36 | $550 |
| Boehringer Ingelheim | 26 | $454 |
| Gilead | 19 | $410 |
| Novartis | 10 | $363 |
| Verona Pharma, Inc. | 19 | $294 |
| Advanced Respiratory, Inc | 10 | $263 |
| Amgen | 11 | $240 |
| Mylan Specialty L.p. | 11 | $224 |
| Baxter Healthcare | 9 | $212 |
| Bayer | 1 | $200 |
| Genentech USA, Inc. | 4 | $190 |
| Philips North America LLC | 10 | $158 |
| Genentech, Inc. | 1 | $150 |
| ANI Pharmaceuticals, Inc. | 8 | $145 |
| Grifols USA, LLC | 4 | $89 |
| La Jolla Pharmaceutical Company | 4 | $75 |
| Viatris Specialty LLC | 3 | $62 |
| AbbVie | 3 | $55 |
| Paratek Pharmaceuticals, Inc. | 3 | $52 |
| Vifor Pharma, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| Shionogi Inc | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Melinta Therapeutics, LLC | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $17 |
| Beckman Coulter, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$85,574 in reported general payments places this provider in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 24 | $596,291 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 560 | $433,754 |
| OfevNintedanib Esylate | 32 | $416,497 |
| Dupixent PenDupilumab | 92 | $345,091 |
| OpsumitMacitentan | 18 | $227,207 |
| TezspireTezepelumab-Ekko | 41 | $173,000 |
| Fasenra PenBenralizumab | 22 | $121,309 |
| Breo ElliptaFluticasone/Vilanterol | 252 | $118,508 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 155 | $118,147 |
| Pirfenidone | 12 | $109,020 |
| Ambrisentan | 21 | $69,715 |
| SymbicortBudesonide/Formoterol Fumarate | 159 | $46,518 |
| Spiriva RespimatTiotropium Bromide | 57 | $43,200 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $32,017 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 50 | $28,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,590 | $601,419896 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $454 | $514,096178 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Airsupra | $72,580 | $349,944374 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $819 | $227,20718 claims |
| MerckDulera, Asmanex | $567 | $23,57566 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $24 | $7,60618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Columbia
- Richard BoganColumbia$1.1M
- Laura HerpelColumbia$254K
- Jake KriegmdColumbia$112K
- Karla Cruz MorelColumbia$74K
- Gregory FeldmanColumbia$73K
- Carlton CauthenColumbia$17K
- Liang ZhaColumbia$10K
- Todd GandyColumbia$10K
- Matthew VarnerColumbia$9K
- Abhijit RavalAnderson$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.